matthias steger, phd mba
ceo and co-founder
Matthias Steger's long career in pharma and biotech began with F. Hoffmann-La Roche
in 1999, when he worked in the design and synthesis of active molecules for a
variety of therapeutic indications - next, he joined Axovan (later acquired by
Actelion), where he built and implemented a new platform for orphan GPCR drug
discovery - Matthias then branched out into investment banking at Kepler Equities
before returning to Roche in 2007 - he became the firm’s global head of research and
technology partnering, a role in which he investigated and managed more than 50
collaborations - in 2015 he followed his strong entrepreneurial instincts, first
establishing SequelBlu, an independent advisory firm aimed at assisting companies
with sustainable innovation, and then endogena.
Matthias earned his MSc in organic chemistry and biochemistry at the University of
Zurich, and his PhD in medicinal chemistry at the University of Sussex. In 2005 he
completed an MBA at the University of St Gallen, where he was awarded Dean’s Honors.